Galli (Sacco): “New anti-herpes zoster vaccine has high efficacy”

The new herpes zoster vaccine “from zero to three years has an efficacy of 97.4%, I would say exceptionally good and which is confirmed in a relevant way in the long term (7 years) at 84%”. This was stated by Massimo Galli, director of Infectious Diseases at the Sacco hospital in Milan, in his speech at the webinar ‘Vax on / zoster off – the new paradigm for the prevention of herpes zoster finally available in Italy’. Read also “Those who work in the clinic cannot fail to have encountered acute pain, and the metameric vesicular rash of herpes zoster – recalled Galli – This is an element that causes a certain annoyance and should not be underestimated also. “importance of the consequences of ophthalmic herpes. Herpes zoster has a chronic phase that affects an important percentage of the population, which is seen to put at risk the quality of life. Postherpetic neuralgia is a frequent complication and not curable effectively. Furthermore, in the subsequent period of acute illness, there is a greater risk of cerebral vascular phenomena with severe partial hearing loss “.